What are the potential long-term economic and business effects of the massive protests sweeping Hong Kong?
Both the NFL and its adversaries pointed to the low number of blacked-out games as a reason the FCC should rule in their favor in a dispute over a regulation giving the league the power to punish fans for staying home
The U.S. has precisely the kind of robust infrastructure missing in West African countries struggling to contain the outbreak
Microsoft has given in to critics and brought back the traditional start menu that consumers will recognize from Windows 7
Gross’s success also coincided with one of the best times in history to be a bond investor
Inspired by sculptor Richard Serra, a New Jersey management consultant makes equipment that doesn't dictate how kids play
There are already kimchi and yogurt doughnuts available abroad, but Dunkin' Donuts' top chef sees fermentation coming to the U.S. menu in sandwiches
MBA students from top business schools traveled to the Italian riviera to network with each other in fancy boats last weekend.
Governor Jerry Brown vetoes a union-backed California bill to give franchisees more rights in fights with corporate partners
King of Prussia, Pa.
Founders: Dr. Robert Lefkowitz and Dr. Howard Rockman
VC Investment over the last four quarters: $26.1 million
Trevena, founded in January 2008, is a drug discovery company developing pharmaceuticals that target what are known as G-protein coupled receptors. Such drugs make up more than 40% of marketed drugs today, according to Trevena. The company's drug discovery platform is based on research from Duke University Medical Center, including that of founder and National Medal of Science winner Robert Lefkowitz.
Key to startup success: "We've been able to generate the strong investor support for this idea [because] the technology and the opportunity here is very, very unique, and the possibility of unlocking new areas of biology is so significantly different from what's currently out there."